OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration

Table 1

Information on the patient sample included in this study.

Characteristics	TCGA	Clinical samples
	537	10
Pathologic T stage, (%)	537	10
T1-2	344 (64.1%)	6 (60.0%)
T3-4	193 (35.9%)	1 (10.0%)
Pathologic N stage, (%)	257	5
N0	240 (93.4%)	5 (100.0%)
N1	17 (6.6%)	0 (0.0%)
Pathologic M stage, (%)	505	9
M0	426 (84.4%)	8 (88.9%)
M1	79 (15.6%)	1 (11.1%)
Pathologic stage, (%)	534	10
Stage I-II	326 (61.0%)	8 (80.0%)
Stage III-IV	208 (39.0%)	2 (20.0%)
Gender, (%)	537	10
Female	191 (35.6%)	4 (40.0%)
Male	346 (64.4%)	6 (60.0%)
Age, (%)	537	10
≤60	266 (49.5%)	4 (40.0%)
>60	271 (50.5%)	6 (60.0%)
Histologic grade, (%)	529	9
G1-2	244 (46.1%)	5 (55.6%)
G3-4	285 (53.9%)	4 (44.4%)